Oxurion NV (GB:0G99) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oxurion NV has successfully terminated its private judicial reorganization procedure after reaching amicable agreements with its key creditors, reducing its debt from €14.7 million to €11.2 million. The company, which focuses on therapies for retinal diseases, is not actively negotiating further agreements but may do so in the future.
For further insights into GB:0G99 stock, check out TipRanks’ Stock Analysis page.
